U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000105: Actibelt® in Sarcopenia
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000105: Actibelt® in Sarcopenia

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Cardiology, Hematology, Endocrinology, and Nephrology (OCHEN)
Division of General Endocrinology (DGE)

DDT COA Number
DDT COA #000105

Instrument Name
Actibelt® in Sarcopenia


Concept of Interest
change in real-world walking speed

Context of Use
Patients with sarcopenia in recovery after surgical treatment of hip fracture

COA Type
DHT- Passive Monitoring COA

Qualification Stage
Letter of Intent- Accepted 

Martin Daumer

Martin Daumer

Date Accepted into CDER’s COA Qualification Program
January 18, 2019

Submission and Regulatory Correspondence History

Qualification Submission Date FDA Submission Decision & Recommendations Date

Letter of Intent



FDA Response (Accepted)



Back to Top